Novartis Ag (NVS) Acquisitions (2009 - 2025)
Novartis Ag (NVS) posted Acquisitions of -$21.0 million for Q4 2025, down 2200.0% sequentially from $1.0 million in Q3 2025, and up 95.07% YoY from -$10.8 million in Q4 2024.
Novartis Ag (NVS) Acquisitions (2009 - 2025) Analysis & Trends
Novartis Ag has reported Acquisitions for 13 years, with the latest figure at -$21.0 million in Q4 2025.
- Quarterly Acquisitions rose 95.07% year-over-year to -$21.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$584.0 million (up 84.98% YoY) and the FY2025 annual result came in at -$147.0 million, up 96.24% from the prior year.
- Acquisitions declined to -$21.0 million in Q4 2025 per NVS's latest filing, from $1.0 million in the prior quarter.
- Over five years, Acquisitions peaked at $1.0 million in Q3 2025 and troughed at -$3.3 billion in Q2 2024.
- A 4-year average of -$513.0 million and a median of -$71.5 million in 2022 frame the typical range for Acquisitions.
- The sharpest annual moves came in 2024 and 2025: Acquisitions sank 3851.19% in 2024, then surged 101.72% in 2025.
- Over 4 years, Acquisitions stood at -$59.0 million in 2022, then slumped by 42.37% to -$84.0 million in 2023, then sank by 407.14% to -$426.0 million in 2024, then soared by 95.07% to -$21.0 million in 2025.
- According to Business Quant data, Acquisitions over the past three periods registered -$21.0 million, $1.0 million, and -$138.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -17.24 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.21 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -21.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Jun 30, 2025 | -138.00 Mn |
| Dec 31, 2024 | -426.00 Mn |
| Sep 30, 2024 | -58.00 Mn |
| Jun 30, 2024 | -3.32 Bn |
| Jun 30, 2023 | -84.00 Mn |
| Jun 30, 2022 | -59.00 Mn |
| Jun 30, 2019 | -286.00 Mn |
| Jun 30, 2018 | -8.35 Bn |
| Jun 30, 2017 | 4.00 Mn |
| Dec 31, 2015 | -135.00 |
| Sep 30, 2015 | -228.00 |
| Jun 30, 2015 | -124.00 |
| Dec 31, 2014 | -350.00 |
| Sep 30, 2014 | -2.00 |
| Jun 30, 2014 | 114.00 |
| Mar 31, 2014 | -93.00 |
| Dec 31, 2013 | -32.00 |
| Sep 30, 2013 | -10.00 |